News | October 17, 2023
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The company has extended its full co-operation and support to the officials of the Income Tax Department
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
The product will be manufactured at Lupin's facility in Nagpur, India.
She joins Enveda from Gilead Sciences
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Subscribe To Our Newsletter & Stay Updated
